TSS
RPRX

Two Sigma Securities’s Repros Therapeutics Inc. RPRX Stock Holding History

Two Sigma Securities’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-10,962
Closed -$4K – 2193
2017
Q3 		$4K Buy
+10,962
New +$3.85K ﹤0.01% 885

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Kassirer Asset Management Toronto, Ontario, Canada $4.07M AUM 49.71% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Securities's RPRX Position: Q4 2017 in Review

Two Sigma Securities sold out of Repros Therapeutics Inc. (RPRX) in Q4 2017, closing a stake of 10,962 shares — an estimated $4K sold.

Two Sigma Securities first reported a position in RPRX in Q3 2017 and held it in 1 quarter. The position peaked at $4K in Q3 2017. 30 funds tracked by Wall St. Rank hold RPRX as of Q4 2017.

  • Two Sigma Securities reported no remaining Repros Therapeutics Inc. position as of Q4 2017 after selling out during the quarter.
  • Two Sigma Securities sold 10,962 Repros Therapeutics Inc. shares in Q4 2017, an estimated $4K.
  • Two Sigma Securities first reported a position in Repros Therapeutics Inc. in Q3 2017 and held it in 1 quarter.
  • Two Sigma Securities's Repros Therapeutics Inc. position peaked at $4K in Q3 2017.
  • 30 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2017.

Based on Two Sigma Securities's 13F filing for Q4 2017, filed 14 Feb 2018.